These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 9635842)

  • 21. Abrogated energy-dependent uptake of cisplatin in a cisplatin-resistant subline of the human ovarian cancer cell line IGROV-1.
    Ma J; Maliepaard M; Kolker HJ; Verweij J; Schellens JH
    Cancer Chemother Pharmacol; 1998; 41(3):186-92. PubMed ID: 9443634
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paclitaxel and SN-38 overcome cisplatin resistance of ovarian cancer cell lines by down-regulating the influx and efflux system of cisplatin.
    Komuro Y; Udagawa Y; Susumu N; Aoki D; Kubota T; Nozawa S
    Jpn J Cancer Res; 2001 Nov; 92(11):1242-50. PubMed ID: 11714450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Breast cancer resistance protein-mediated topotecan resistance in ovarian cancer cells.
    Jia P; Wu S; Li F; Xu Q; Wu M; Chen G; Liao G; Wang S; Zhou J; Lu Y; Ma D
    Int J Gynecol Cancer; 2005; 15(6):1042-8. PubMed ID: 16343180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Topotecan-induced alterations in the amount and stability of human DNA topoisomerase I in solid tumor cell lines.
    Devy J; Wargnier R; Pluot M; Nabiev I; Sukhanova A
    Anticancer Res; 2004; 24(3a):1745-51. PubMed ID: 15274350
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of topoisomerase I catalytic activity as determinant of drug response in human cancer cell lines.
    Voigt W; Vanhoefer U; Yin MB; Minderman H; Schmoll HJ; Rustum YM
    Anticancer Res; 1997; 17(5A):3707-11. PubMed ID: 9413228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein.
    Jansen WJ; Hulscher TM; van Ark-Otte J; Giaccone G; Pinedo HM; Boven E
    Br J Cancer; 1998; 77(3):359-65. PubMed ID: 9472629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines.
    Keshelava N; Groshen S; Reynolds CP
    Cancer Chemother Pharmacol; 2000; 45(1):1-8. PubMed ID: 10647494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
    Nagashima S; Soda H; Oka M; Kitazaki T; Shiozawa K; Nakamura Y; Takemura M; Yabuuchi H; Fukuda M; Tsukamoto K; Kohno S
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):594-600. PubMed ID: 16520985
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the P-glycoprotein- and breast cancer resistance protein-mediated brain penetration of 11C-labeled topotecan using small-animal positron emission tomography.
    Yamasaki T; Fujinaga M; Kawamura K; Hatori A; Yui J; Nengaki N; Ogawa M; Yoshida Y; Wakizaka H; Yanamoto K; Fukumura T; Zhang MR
    Nucl Med Biol; 2011 Jul; 38(5):707-14. PubMed ID: 21718946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Topotecan inhibits human immunodeficiency virus type 1 infection through a topoisomerase-independent mechanism in a cell line with altered topoisomerase I.
    Zhang JL; Sharma PL; Li CJ; Dezube BJ; Pardee AB; Crumpacker CS
    Antimicrob Agents Chemother; 1997 May; 41(5):977-81. PubMed ID: 9145855
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells.
    Brangi M; Litman T; Ciotti M; Nishiyama K; Kohlhagen G; Takimoto C; Robey R; Pommier Y; Fojo T; Bates SE
    Cancer Res; 1999 Dec; 59(23):5938-46. PubMed ID: 10606239
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
    Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
    Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary.
    Itamochi H; Kigawa J; Sultana H; Iba T; Akeshima R; Kamazawa S; Kanamori Y; Terakawa N
    Jpn J Cancer Res; 2002 Jun; 93(6):723-8. PubMed ID: 12079522
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The current status of camptothecin analogues as antitumor agents.
    Slichenmyer WJ; Rowinsky EK; Donehower RC; Kaufmann SH
    J Natl Cancer Inst; 1993 Feb; 85(4):271-91. PubMed ID: 8381186
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
    Takiguchi S; Kumazawa E; Shimazoe T; Tohgo A; Kono A
    Jpn J Cancer Res; 1997 Aug; 88(8):760-9. PubMed ID: 9330608
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials.
    Tanizawa A; Fujimori A; Fujimori Y; Pommier Y
    J Natl Cancer Inst; 1994 Jun; 86(11):836-42. PubMed ID: 8182764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
    Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An enhanced active efflux of CPT-11 and SN-38 in cisplatin-resistant human KB carcinoma cells.
    Chen ZS; Sumizawa T; Furukawa T; Ono K; Tani A; Komatsu M; Akiyama S
    Cancer Lett; 1999 Apr; 138(1-2):13-22. PubMed ID: 10378768
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters.
    Takagi K; Dexheimer TS; Redon C; Sordet O; Agama K; Lavielle G; Pierré A; Bates SE; Pommier Y
    Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3229-38. PubMed ID: 18089716
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of resistance to Aplidin in a human ovarian cancer cell line related to MDR expression.
    Tognon G; Bernasconi S; Celli N; Faircloth GT; Cuevas C; Jimeno J; Erba E; D'Incalci M
    Cancer Biol Ther; 2005 Dec; 4(12):1325-30. PubMed ID: 16258264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.